Log In
Print
BCIQ
Print
Print this Print this
 

Nalbuphine ER (T111)

  Manage Alerts
Collapse Summary General Information
Company Endo International plc
DescriptionExtended-release oral formulation of nalbuphine, a mu opioid receptor (OPRM1; MOR) antagonist and kappa opioid receptor (OPRK1; KOR) agonist
Molecular Target Mu opioid receptor (OPRM1) (MOR) ; Kappa opioid receptor (OPRK1) (KOR)
Mechanism of ActionKappa opioid receptor agonist; Mu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationItch
Indication DetailsTreat hemodialysis-related uremic pruritus; Treat prurigo nodularis
Regulatory Designation

Partner

Trevi Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today